Effect of Preoperative Diclofenac Potassium on Articaine Buccal Infitration Success

Model scores of the 29,894 trials active now.

Model score 7% for any early termination, 3% for termination due to slow enrollment. Past trials like this one (phase, sponsor type and disease area, started 2008–2016) ended terminated 10% of the time (273 trials).

Finished trial that started in 2015 or later: the model never saw it during training.

Cumulative chance of ending terminated (red) or completed (green) by each year from its start; it actually ended on 2018-04-30. The rest of the way to 100% is still running.

From the competing-risks survival model (termination vs completion, still-running trials censored), fit to trials that started 2008–2014 and recalibrated to termination rates over 2022–2024, since termination has become more common. Checked on past years, it still ran a little low when the rise continued.

• Sponsor's past termination rate: 0.8% (lowers risk) · Sponsor's track record
• Wording of the registration (title, summary, criteria) (lowers risk) · Wording Phrases that raised it: patientpatientsmoderate toto severepain
  Phrases that lowered it: effect ofthe effectallergiesdiclofenacperiodontal
• Accepts healthy volunteers: No (raises risk) · Who can join
• Primary purpose: prevention (lowers risk) · Design
• Trials the sponsor started in the prior 2 years: 157 (lowers risk) · Sponsor's track record
• Blinding: quadruple (lowers risk) · Design
• Design: parallel (raises risk) · Design
• Disease area, cancer: No (lowers risk) · Disease area
• Drug's FAERS reports with a death: 8.8% (lowers risk) · Drug's FDA history
• Responsible party: principal investigator (lowers risk) · Design
• Sponsor type: academic or other (raises risk) · Sponsor's track record
• Minimum age: 18 (raises risk) · Who can join
• Drug's FAERS reports marked serious: 75.5% (lowers risk) · Drug's FDA history
• Has a data monitoring committee: No (lowers risk) · Design
• Number of arms: 2 (raises risk) · Design
• Sponsor's past trials: 119 (lowers risk) · Sponsor's track record
• Maximum age: 60 (lowers risk) · Who can join
• Disease area, neurology: No (lowers risk) · Disease area

Every input that moved this score, largest first: SHAP contributions in log-odds, red raising risk and green lowering it. They describe the model, not causes of termination. Phrases are traced from the text features back to this registration's words, approximately.

• Effect of Preoperative Diclofenac Potassium on Postoperative Endodontic Pain NCT03341260 · started 2016 · scored riskier than 9% of active trials completed
• Effect of Preoperative Oral Ibuprofen on Anesthetic Efficacy of Inferior Alveolar Nerve Block With Supplemental Buccal and Lingual Infiltrations Using Articaine in Mandibular Molar Teeth With Irreversible Pulpitis NCT05927922 · started 2023 · scored riskier than 6% of active trials completed
• 4% Articaine and 2% Lidocaine by Intraligamentary Technique in Irreversible Pulpitis NCT02807298 · started 2014 · scored riskier than 10% of active trials completed
• Effect of Preoperative Tramadol and Naproxen Sodium on Post Operative Pain NCT05982392 · started 2023 · scored riskier than 4% of active trials completed
• Efficacy of Ketorolac Buccal Infiltration on Success Rate of Inferior Alveolar Nerve Block NCT02536430 · started 2015 · scored riskier than 9% of active trials completed

Closest by meaning of the registration text (PubMedBERT embeddings), among finished trials. How they ended is context, not an input to this trial's score.